Galapagos to Acquire CellPoint and AboundBio to Advance Cell Therapies for the Treatment of Advanced Cancer
Shots:
- Galapagos to acquire all outstanding shares of CellPoint & AboundBio in an all-cash transaction which consists of $131.20M up front for CellPoint with additional fees of $104.96M upon achievement of milestones & $14M for AboundBio
- The acquisition will combine CellPoint’s decentralized point-of-care manufacturing model with Lonza & AboundBio’s human Ab-based capabilities & biological drug capabilities to develop 3 additional CAR-T candidates for the clinic over the next 3yrs.
- The acquisition also broadens Galapagos’ portfolio & capabilities. The results from an ongoing 2 P-I/IIa studies for r/rNHL & r/rCLL, which are clinically validating the decentralized production platform with CD19 CAR-T are anticipated in H1'23
Ref: GlobalNewswire | Image: Galapagos
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
